BELANOFF JOSEPH K 4

What Happened
Joseph K. Belanoff, CEO of Corcept Therapeutics (CORT), received a derivative award for 460,000 shares on February 27, 2026. The award was reported as acquired at $0.00 (no cash paid) and is a time-based equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: February 27, 2026; Form 4 filed March 3, 2026 (no notation in the filing that it was late).
• Transaction type/code: Award/Grant (derivative acquisition), 460,000 shares, $0.00 per share.
• Vesting: Per footnote F1, the award vests ratably in equal installments on each monthly anniversary of Feb 27, 2026 over a four-year period, subject to continued service through each vesting date.
• Shares owned after transaction: Not specified in the provided filing details.
• Remarks: Form signed under a power of attorney on file with the SEC.

Context

• This grant is a time-based equity award (commonly restricted stock units or similar) that will convert into actual shares as it vests; there was no immediate sale or cashless exercise reported.
• Such grants are routine for executives as part of compensation and do not by themselves indicate the insider’s intent to buy or sell shares in the open market.